Literature DB >> 9788674

Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1.

J J Kort1.   

Abstract

Perturbation of astrocyte functions by HIV-1 infection may contribute to the pathogenesis of AIDS dementia complex (ADC). The present study investigated the possibility that astroglial transport of glutamate and aspartate, the major excitatory amino acids (EAAs) in the mammalian central nervous system (CNS), is altered by HIV-1 infection. Human U251 glioma cells were infected with the brain isolate SF162 of HIV-1. HIV-1 persisted in glial cells over several months. This nonproductive infection of glial cells was characterized by persistent expression of Nef over the time of the infection, and the transient presence of structural viral proteins, including the viral transmembrane glycoprotein gp41, which was detected during the initial 2 weeks following HIV-1 infection. The presence of gp41 in acutely HIV-1-infected glial cells coincided with a 36% decrease in D-[3H]aspartate uptake, owing to a reduction in the maximal transport capacity (vmax) for D-aspartate. The expression of typical astrocytic glutamate transporters EAAT1 and EAAT2 in U251 glioma cells was not altered by HIV-1 infection. To determine whether viral protein gp120, gp41, or Nef was involved in the impairment of EAA transport in acutely HIV-1-infected glial cells, effects of lentiviral lytic peptide type 1 (LLP-1) (corresponding to the carboxy terminus of gp41), recombinant SF2 gp120, and recombinant LAI Nef on D-[3H]aspartate uptake and the release of glutamate in glial cells were investigated. Only LLP-1 reduced D-[3H]aspartate uptake and facilitated the release of glutamate from glial cells in a concentration-dependent manner. These results suggest that the carboxy terminus of gp41 impairs EAA transport in glial cells, which may contribute to excitotoxic damage to neurons in HIV-1 infection of the CNS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788674     DOI: 10.1089/aid.1998.14.1329

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

3.  Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons.

Authors:  Cornelia Speth; Thomas Schabetsberger; Iradji Mohsenipour; Gabriele Stöckl; Reinhard Würzner; Heribert Stoiber; Cornelia Lass-Flörl; Manfred P Dierich
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS.

Authors:  Dima A Hammoud; Christopher J Endres; Ankit R Chander; Tomas R Guilarte; Dean F Wong; Ned C Sacktor; Justin C McArthur; Martin G Pomper
Journal:  J Neurovirol       Date:  2005-08       Impact factor: 2.643

5.  Protective effect of glutathione in HIV-1 lytic peptide 1-induced cell death in human neuronal cells.

Authors:  J H Sung; S A Shin; H K Park; R C Montelaro; Y H Chong
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

6.  Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells.

Authors:  Diane M P Lawrence; Linda C Durham; Lynnae Schwartz; Pankaj Seth; Dragan Maric; Eugene O Major
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 7.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 8.  Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders.

Authors:  Michelle C Potter; Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-04       Impact factor: 4.147

9.  Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein.

Authors:  Joshua M Costin; Joshua M Rausch; Robert F Garry; William C Wimley
Journal:  Virol J       Date:  2007-11-20       Impact factor: 4.099

Review 10.  Cytopathic mechanisms of HIV-1.

Authors:  Joshua M Costin
Journal:  Virol J       Date:  2007-10-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.